VolitionRx Announces Collaboration with Sysmex
VolitionRx entered a collaboration with Sysmex to optimize its Nu.Q® NETs H3.1 assay on Sysmex's global in vitro diagnostics platform. The partnership leverages Sysmex's installed base and regulatory expertise to target diseases associated with NETosis, such as sepsis, where Volition believes its test can improve clinical decision-making.
Key figures
- Tam
- $3.8 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.